Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000248852 | SCV000316906 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV003105841 | SCV002363315 | likely benign | Dyskeratosis congenita, autosomal dominant 2; Idiopathic Pulmonary Fibrosis | 2024-01-25 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004558608 | SCV002716817 | uncertain significance | Dyskeratosis congenita | 2015-07-16 | criteria provided, single submitter | clinical testing | The c.1769+16G>A intronic variant results from a G to A substitution 16 nucleotides after coding exon 3 in the TERT gene. This variant was previously reported in the SNPDatabase as rs202108457. Based on data from the NHLBI Exome Sequencing Project (ESP), the A allele has an overall frequency of approximately 0.01% (1/13006) total alleles studied and 0.01% (1/8600) European American alleles. This nucleotide position is poorly conserved in available vertebrate species on limited alignment. In addition, A is the reference nucleotide in multiple species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is not predicted to have any significant effect on this acceptor/donor splice site; however, direct evidence is unavailable. Since supporting evidence is limited at this time, the clinical significance of this variant remains unclear. |